Good Time to Revisit Apricus Biosciences APRI

As year end tax selling, etc. comes to an end, it seems a good time to take a look at Apricus Biosciences (APRI) with $43M market cap and enterprise value, net of cash & LT debt of $33M.
One approved erectile dysfunction drug shipping in Europe and two phase two trials being conducted in 2015. New market launches in Europe for its ED drug and the 2 trials should provide solid news flow in 2015.

APRI Update

Posts that I make on Investors Hangout reflect my own personal thinking and opinion and are neither endorsed nor approved by the subject companies, many of which may be clients or client prospects of our our NY-based investor relations consulting firm.

David Collins, Managing Director
Catalyst Global Investor Relations
www.catalyst-ir.com
dcc@catatalyst-ir.com
212 924 9800